# Understanding the Liraglutide Sequence: A Personal Review of Structural Profiles
As a enthusiast in the field of peptide research and biochemistry, I have spent considerable time analyzing the foundational molecular architecture of various GLP-1 analogs. Among these, the liraglutide sequence stands out as a fascinating example of protein engineering. My interest in this molecule stems from a desire to understand how slight chemical modifications can dramatically alter the pharmacokinetics of a peptide chain.
At its core, liraglutide is an acylated derivative of human glucagon-like peptide-1 (GLP-1). When evaluating the liraglutide amino acid sequence, I found it essential to compare it to the native human GLP-1 (7-37). The primary structure is defined by the following sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu May 20, 2026 · The sequence of the GLP-1 peptide and a few reported GLP-1RAs, like Exendin-4, Semaglutide, Liraglutide, and … -Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.
To understand why this sequence is unique, researchers often look at the liraglutide sequence FASTA format. The most critic Sep 15, 2025 · CID 16153050 | C172H265N43O51 | CID 16153050 - structure, chemical names, physical and chemical properties, … al modification is the substitution of lysine at position 34 with arginine (Arg34) and the attachment of a C16 fatty acid chain (palmitoyl group) to the lysine residue at position 26 (often documented as position 27 in specific nomenclature). This specific structural tweak is what gives the molecule its 97% sequence homology to human GLP-1 while allowing it to bind to albumin for extended activity.
Comparative Analysis: Liraglutide Structure and Family Members
When hobbyists look at the liraglutide structure, they often find themselves comparing it to other incretin mimetics. A frequent question is, is liraglutide a peptide? The answer is unequivocally yes. It is an acylated peptide, which distinguishes it from simpler chain-based structures Liraglutide | 204656-20-2 - ChemicalBook .
In my own review of advanced proteomics, I frequently contrast this with the s VICTOZA (liraglutide) injection emaglutide sequence. While both are GLP-1 receptor agonists, semaglutide f KEGG DRUG: Liraglutide - GenomeNet eatures a different spacer and a C18 di-acid fatty chain attached to the lysine, which significantly distinguishes how it interacts with the receptor compared to the liraglutide profile. Understanding the liraglutide molecular weight—which sits approximately at 3751.2 Da—is crucial for anyone involved in analytical chemistry or peptide synthesis.
Practical Observations on Research Applications
In the broader context of chemical study, many researchers look toward the indications for liraglutide as a benchmark for how long-acting agonists perform. By observing the stability provided by the palmitoyl fatty acid chain, it becomes clear why this specific structural modification is a hallmark of modern peptide science. Whether one is reviewing the liraglutide FDA indication or simply exploring the chemical properties of an acylated GLP-1 analog, the rigor applied to its synthesis ensures a consistent profile.
For those conducting laboratory analysis, the data available through databases like PubChem and UniProt provides clear insights into the polypeptide chain’s integrity. My personal takeaway from reviewing these records is that the precision of the sequence, combined with the specific site of acylation, remains a gold standard in the study of synthetic incretin mimetics.
*
Terminology/Data Reference UniProt Summary:
* Entity: Liraglutide (C172H265N43O51)
* LSI: GLP-1 receptor agonist, Palmitoyl-Lys, Albumin b RCSB PDB - 4APD: Liraglutide inding, Peptide synthesis.
* Variation:** Human GLP-1 analog, Acylated peptide, Incretin mimetic.
*Disclaimer: This information is for educational and research purposes only. I am not a medical professional, and this content does not constitute medical advice or instructions on human use.*
# Understanding the Liraglutide Sequence: A Personal Review of Structural Profiles
As a enthusiast in the field of peptide research and biochemistry, I have spent considerable time analyzing the foundational molecular architecture of various GLP-1 analogs. Among these, the liraglutide sequence stands out as a fascinating example of protein engineering. My interest in this molecule stems from a desire to understand how slight chemical modifications can dramatically alter the pharmacokinetics of a peptide chain.
At its core, liraglutide is an acylated derivative of human glucagon-like peptide-1 (GLP-1). When evaluating the liraglutide amino acid sequence, I found it essential to compare it to the native human GLP-1 (7-37). The primary structure is defined by the following sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu May 20, 2026 · The sequence of the GLP-1 peptide and a few reported GLP-1RAs, like Exendin-4, Semaglutide, Liraglutide, and … -Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.
To understand why this sequence is unique, researchers often look at the liraglutide sequence FASTA format. The most critic Sep 15, 2025 · CID 16153050 | C172H265N43O51 | CID 16153050 - structure, chemical names, physical and chemical properties, … al modification is the substitution of lysine at position 34 with arginine (Arg34) and the attachment of a C16 fatty acid chain (palmitoyl group) to the lysine residue at position 26 (often documented as position 27 in specific nomenclature). This specific structural tweak is what gives the molecule its 97% sequence homology to human GLP-1 while allowing it to bind to albumin for extended activity.
Comparative Analysis: Liraglutide Structure and Family Members
When hobbyists look at the liraglutide structure, they often find themselves comparing it to other incretin mimetics. A frequent question is, is liraglutide a peptide? The answer is unequivocally yes. It is an acylated peptide, which distinguishes it from simpler chain-based structures Liraglutide | 204656-20-2 - ChemicalBook .
In my own review of advanced proteomics, I frequently contrast this with the s VICTOZA (liraglutide) injection emaglutide sequence. While both are GLP-1 receptor agonists, semaglutide f KEGG DRUG: Liraglutide - GenomeNet eatures a different spacer and a C18 di-acid fatty chain attached to the lysine, which significantly distinguishes how it interacts with the receptor compared to the liraglutide profile. Understanding the liraglutide molecular weight—which sits approximately at 3751.2 Da—is crucial for anyone involved in analytical chemistry or peptide synthesis.
Practical Observations on Research Applications
In the broader context of chemical study, many researchers look toward the indications for liraglutide as a benchmark for how long-acting agonists perform. By observing the stability provided by the palmitoyl fatty acid chain, it becomes clear why this specific structural modification is a hallmark of modern peptide science. Whether one is reviewing the liraglutide FDA indication or simply exploring the chemical properties of an acylated GLP-1 analog, the rigor applied to its synthesis ensures a consistent profile.
For those conducting laboratory analysis, the data available through databases like PubChem and UniProt provides clear insights into the polypeptide chain’s integrity. My personal takeaway from reviewing these records is that the precision of the sequence, combined with the specific site of acylation, remains a gold standard in the study of synthetic incretin mimetics.
*
Terminology/Data Reference UniProt Summary:
* Entity: Liraglutide (C172H265N43O51)
* LSI: GLP-1 receptor agonist, Palmitoyl-Lys, Albumin b RCSB PDB - 4APD: Liraglutide inding, Peptide synthesis.
* Variation:** Human GLP-1 analog, Acylated peptide, Incretin mimetic.
*Disclaimer: This information is for educational and research purposes only. I am not a medical professional, and this content does not constitute medical advice or instructions on human use.*